AVADEL PHARMACEUTICALS PLC Amended Passive Investment Disclosure
Avadel Pharmaceuticals plc received an amended Schedule 13G/A from investment entities associated with Jeffrey L. Gendell, reporting a reduced ownership position below the 5% threshold.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Avadel Pharmaceuticals plc received an amended Schedule 13G/A from investment entities associated with Jeffrey L. Gendell, reporting a reduced ownership position below the 5% threshold. This amendment is described as an exit filing for the reporting persons.
Mr. Gendell reports beneficial ownership of 4,839,357 American Depositary Shares, or 4.9% of Avadel’s ordinary shares outstanding. Within this total, Tontine Capital Overseas Master Fund II, L.P. and Tontine Asset Associates, LLC each report beneficial ownership of 2,859,475 American Depositary Shares, or approximately 2.9% of the outstanding ordinary shares.
Insights
Key Avadel holder now reports a 4.9% stake, triggering an exit-type ownership filing.
Investment entities linked to Jeffrey L. Gendell report beneficial ownership of 4,839,357 Avadel American Depositary Shares, equal to 4.9% of ordinary shares outstanding. This falls below the 5% reporting threshold, and the amendment is characterized as an exit filing for the reporting group.
Within this structure, Tontine Capital Overseas Master Fund II, L.P. and Tontine Asset Associates, LLC each report 2,859,475 American Depositary Shares, or about 2.9% of the ordinary shares, based on 98,153,471 shares outstanding as of November 25, 2025. The certification states the holdings are not for changing or influencing control.
The filing signals that these investors currently remain significant but non‑5% holders. Future ownership updates, if any, would be reflected in subsequent beneficial ownership reports should their stake again cross relevant regulatory thresholds.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the latest Schedule 13G/A filing report for Avadel (AVDL)?
What stake in Avadel (AVDL) is held by Tontine Capital Overseas Master Fund II, L.P.?
Why is this Avadel (AVDL) Schedule 13G/A called an exit filing?
AI-generated analysis. How Rhea-AI works. Not financial advice.